
Congress Impact & Policy Brief Development
Analyze legislation for clinical impact and generate policy briefs for government relations teams.
What You Can Do
You can quickly translate pending legislation into structured policy analysis that your government relations team can use immediately. The skill analyzes bills for clinical relevance, identifies potential impacts on your pipeline and indication strategy, and generates executive-ready briefs that frame your company's scientific position on healthcare policy issues. This accelerates your ability to inform advocacy conversations before they happen on Capitol Hill.
Features
Systematically evaluate bills for clinical implications, regulatory triggers, and reimbursement impacts specific to your therapeutic area
Map legislation against your pipeline timeline, indication strategy, and commercial objectives to quantify risk and opportunity
Translate clinical trial data, real-world evidence, and mechanism-of-action science into policy-relevant arguments
Identify what Congress cares about (access, cost, efficacy, safety) and align your clinical narrative accordingly
Develop evidence-based responses to opposing viewpoints on drug pricing, FDA authority, or indication expansion policies
Generate formatted policy briefs with key findings, talking points, and supporting evidence ready for Gov Relations distribution
Rapidly assess Congressional hearing topics and build clinical Q&A materials for agency testimony or stakeholder coordination
Example Output
Example 1: Drug Pricing Bill Analysis
Input: "H.R. 1234 proposes Medicare negotiation powers for 50+ drugs. Our pipeline includes [drug name] launching in 18 months with indication [X]. Analyze clinical/commercial impact."
Output:
- Bill Summary: Grants HHS authority to negotiate prices for drugs meeting usage/spending thresholds; applies 9-year exclusivity from negotiation
- Clinical Relevance: Your drug's mechanism (GLP-1 agonist) directly addresses Congress's stated concern (cost/efficacy gap in Type 2 diabetes); strong RCT data on cardiovascular outcomes supports access argument
- Company Risk: Launch timing places drug in negotiation window; excludes new orphan indications
- Policy Position: Frame around patient access data + real-world evidence on cost-effectiveness vs. comparators
- Talking Points for Gov Relations:
- "Evidence shows our therapy reduces downstream complications, offsetting acquisition costs"
- "Exclusivity period misaligned with indication expansion timelines"
Example 2: FDA Authority Hearing Prep
Input: "Senate HELP Committee hearing on accelerated approval pathways. Our drug uses Breakthrough Therapy designation. Build Q&A for our clinical lead."
Output:
- Likely Questions: Safety signal management? Real-world evidence post-approval? Indication creep risks?
- Clinical Answers: (with supporting trial data, comparator data, and trial design rationale)
- Risk Areas: Address concerns Congress has about accelerated approvals; prepare nuanced responses
What's Included
- SKILL.md instruction file with legislative analysis framework and when/when-not-to-use triggers:
- Congressional Bill Analysis Template: structured worksheet to evaluate bills for clinical implications, company impact, and policy positioning
- Policy Brief Format Guide: executive brief template with sections for clinical findings, business impact, and government relations talking points
- Evidence Synthesis Checklist: framework for translating clinical trial data, real-world evidence, and mechanism-of-action science into policy arguments
- Hearing Prep Workbook: Q&A builder for Congressional hearing scenarios with clinical response frameworks
Who It's For
- Medical Affairs Managers in pharmaceutical/biotech companies tracking healthcare legislation
- Government Relations teams needing rapid clinical input before Congressional advocacy
- Clinical Operations leads supporting policy/regulatory strategy planning
- Reimbursement and health economics professionals translating clinical evidence into healthcare policy arguments
- Regulatory Affairs managers coordinating clinical perspective on FDA/Congressional hearing testimony
Best For
- Rapid bill analysis when new healthcare legislation is introduced (drug pricing, FDA authority, indication expansion, drug importation)
- Government relations briefing prep — translating clinical data into policy arguments for Hill staff meetings
- Congressional hearing preparation — building clinical Q&A and evidence frameworks for agency testimony or stakeholder coordination
- Policy positioning development — structuring your company's scientific stance on pending legislation
- Counter-argument development — generating evidence-based responses to opposing healthcare policy positions







